HuGE Literature Finder
Records 1-4
|
Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.
Clinical breast cancer 2017 Jun . Yokoyama Satoshi, Tamaru Satoshi, Tamaki Shinya, Nakanishi Daisuke, Mori Akiya, Yamakawa Tomokazu, Ao Takaaki, Sakata Yasuhiko, Mizuno Toshiro, Iwamoto Takuya, Watanabe Kenichi, Simomura Makoto, Kawakami Keiki, Konishi Naomi, Kageyama Shinichi, Ohtani Shoichiro, Yamada Tomomi, Ban Susumu, Ooi Kazu |
|
Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients.
Pharmacotherapy 2017 Mar . Genvigir Fabiana D V, Nishikawa Alvaro M, R Felipe Claudia, Tedesco-Silva Helio, Oliveira Nagilla, Salazar Antony B C, Medina-Pestana Jose O, Doi Sonia Q, Hirata Mario H, Hirata Rosario D |
|
Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Pharmacogenomics 2014 15 (12): 1565-74. Lamba Jatinder Kaur, Fridley Brooke L, Ghosh Taraswi M, Yu Qing, Mehta Gaurav, Gupta Pank |
|
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
Cancer chemotherapy and pharmacology 2009 Feb 63 (3): 477-89. O'Bryant C L, Lieu C H, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz M K, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt S |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 27, 2021
- Content source: